Treatment of Primary Liver Tumors With Electrochemotherapy (ECT) (ECT-HCC)

July 2, 2021 updated by: Masa Bosnjak

The aim of the study is to evaluate toxicity and effectiveness of electrochemotherapy with bleomycin in treatment of primary liver tumors in clinical study phase I and II.

The study will include 10 patients in phase I clinical study and additional 15 patients in phase II clinical study (or in the extension of the clinical study), which will fulfill inclusion criteria.

Treatment effectiveness will be evaluated by DCE-US or CT perfusion, to detect early events in tumor perfusion after ECT compared to tumor perfusion before ECT. Long term effectiveness of the treatment will be evaluated by modified RECIST criteria, which will take into account difference in size and density, determined from images obtained by CT perfusion of the treated tumor nodules before and after ECT. Tumor volume will be calculated by following formula , where a will be shorter and b longer tumor diameter.

The secondary objectives of the trial are to quantify the impact of the treatment on the patient's quality of life, tolerance to the therapy and suitability for larger study to be conducted.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study will be conducted on patients with primary liver tumors. 10 patients will be included in phase I clinical study and additional 15 patients in phase II clinical study (or in the extension of the clinical study).

Depending on the position of tumors, appropriate electrodes will be selected; hexagonal needle electrodes with fixed geometry for tumors not larger than 3 cm in diameter, where lower edge of the tumor is located up to 3 cm below the liver capsule or longer single needle electrodes. Individual electrodes, positioned according to the prepared treatment plan will be used for tumors up to 7 cm in diameter, or located near vena cava or large hepatic or portal veins.

Electrochemotherapy will be performed within 8-28 min after intravenous in bolus administration of bleomycin (15 mg/m2).

Triggering of electric pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart.

All patients will be treated after the procedure has been thoroughly described to them, and have signed informed consent.

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Slovenia
      • Ljubljana, Slovenia, 1000
        • University Medical Centre Ljubljana, Ljubljana, Slovenia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients with primary liver tumors; hepatocellular carcinoma, intrahepatic cholangiocarcinoma and other primary tumors not larger than 7 cm that are positioned in unresectable liver area, near blood vessels in operable patients.

  2. Patients with the progression of the disease (confirmed by radiological imaging) after treatment with TACE, RFA or percutaneous alcohol ablation, which are not suitable for potentially curative treatment, but with relatively good "performance status" and Child-Pugh score < 8.

    Patients from group 1. and 2. are patients, in whom standard treatment procedures are not eligible, so ECT will be the only therapeutic option. In patients with multiple liver tumors, unresectable tumors which are also unsuitable for RAF will be treated by ECT, whereas other tumors will be resected or treated by RAF.

  3. Patients with tumors smaller tumors, not suitable for liver transplantation, but also unsuitable for RFA treatment or percutaneous alcohol ablation because of the position of the tumor. Electrochemotherapy will be as bridge therapy, till liver transplantation.

  4. Patients with tumors> 4 cm in diameter, in difficult to reach locations, and patients unsuitable for treatment with other treatment options.

    Patients from group 3. and 4. are patients, potentially curable with standard treatment. Electrochemotherapy in these patients will not affect the standard of care of these patients, recommended in guidelines for HCC.

  5. Electrochemotherapy is offered to the patients also when they refuse standard treatments.
  6. Histologically confirmed primary liver cancer and/or based on radiological imaging laboratory tests confirmed primary liver cancer by multidisciplinary team for liver tumors.
  7. Age more than 18.
  8. Life expectancy more than 3 month.
  9. Performance status Karnofsky ≥ 70 or (World Health Organization) WHO < or 2.
  10. Treatment free interval 2-5 weeks, depending on the drugs used.
  11. Patient must be mentally capable of understanding the information given.
  12. Patient must give informed consent.
  13. Patient must be discussed at the multidisciplinary team for liver tumors before entering the trial.

Exclusion Criteria:

  1. Secondary primary tumor, except surgically treated noninvasive cancer of cervix, or surgically or irradiated basal cell carcinoma
  2. Visceral, bone or diffuse metastases.
  3. Life-threatening infection and/or heart failure and/or liver failure and/or other severe systemic pathologies.
  4. Clinically significant ascites.
  5. Significant reduction in respiratory function.
  6. Age less than 18 years.
  7. Coagulation disturbances (those who do not respond on standard treatment with vitamin-K or fresh frozen plasma).
  8. Cumulative dose of 250 mg/m2 bleomycin received.
  9. Allergic reaction to bleomycin.
  10. Impaired kidney function (creatinin > 150 µmol/l).
  11. Patients with epilepsy.
  12. Patients with arrhythmias.
  13. Patients with heart failure or pace maker.
  14. Pregnancy.
  15. Patient incapable of understanding the aim of the study or disagree with the entering into the clinical study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Electrochemotherapy treatment
Procedure: Electrochemotherapy
Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
Device: Cliniporator Vitae®

Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.

The maximum duration of procedure is 90 minutes, after liver mobilization.

Drug: Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
Intravenous in bolus administration of bleomycin (15 mg/m2)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Toxicity Related to Electrochemotherapy
Time Frame: After operation on day 7
Biochemistry, blood test and/or US
After operation on day 7

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Response Evaluation According to RECIST v1.1
Time Frame: After operation on days 1, 7, 30, 60, 90, 120

Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI/CT:

Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
After operation on days 1, 7, 30, 60, 90, 120

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Masa Bosnjak

Collaborators

University of Ljubljana
Institute of Oncology Ljubljana

Investigators

  • Principal Investigator: Mihajlo Djokic, MD, University Medical Centre Ljubljana, Ljubljana, Slovenia
  • Principal Investigator: Blaz Trotovsek, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia
  • Study Director: Gregor Sersa, PhD, Institute of Oncology Ljubljana, Slovenia
  • Study Director: Borut Stabuc, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia
  • Study Chair: Dragoje Stanisavljevic, MD, University Medical Centre Ljubljana, Ljubljana, Slovenia
  • Study Chair: Valentin Sojar, MD, PhD, University Medical Centre Ljubljana, Ljubljana, Slovenia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2014

Primary Completion (Actual)

September 1, 2019

Study Completion (Actual)

January 1, 2020

Study Registration Dates

First Submitted

November 6, 2014

First Submitted That Met QC Criteria

November 11, 2014

First Posted (Estimate)

November 14, 2014

Study Record Updates

Last Update Posted (Actual)

July 23, 2021

Last Update Submitted That Met QC Criteria

July 2, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 21K/02/14

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Liver Cancer

Clinical Trials on Electrochemotherapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe